First In-Room MRI-Guided Breast Biopsy System Gets FDA Clearance
Mammotome received FDA clearance for the Prima MR system, the first in‑room MRI‑guided vacuum‑assisted breast biopsy platform, alongside its HydroMARK Plus MR biopsy site markers. The system lets clinicians perform biopsies directly inside the MRI suite, eliminating patient transfers and streamlining workflow. It uses an 8‑gauge needle, 75 % less tubing and a touchscreen interface to improve sample size, targeting accuracy and setup speed. Availability begins this summer in the U.S., with a global rollout planned later in 2026.
Tozorakimab Scores Double Win in Phase III COPD Trials
AstraZeneca announced that its IL‑33 monoclonal antibody tozorakimab achieved its primary endpoints in two Phase III COPD trials, Oberon and Titania. The drug significantly reduced the annual rate of moderate‑to‑severe exacerbations versus placebo across former and current smokers. AstraZeneca positions tozorakimab...
Pharma and Biotech Layoffs 2026 Watch
Pharma and biotech companies continued extensive workforce reductions in early 2026, with Takeda alone eliminating 634 U.S. positions as part of a $1.2 billion annual savings plan, while Amgen, GSK, and Merck KGaA also announced cuts ranging from dozens to several...
Which Pharma Jobs Will Be Most In Demand Over the Next 5 Years?
The pharmaceutical sector is reshaping its workforce as AI, precision medicine, tighter regulations, and global manufacturing scale become central to drug development. Companies are seeking talent that can harness data‑driven discovery, navigate complex clinical trials, and ensure compliance across jurisdictions....
Closing the Gaps in Stroke Care: Access, Innovation and Global Equity
Linnea Burman, President of Medtronic Neurovascular, highlighted that nearly 12 million people suffer a stroke each year and one in four die within a year, underscoring persistent global gaps in prevention, access, and long‑term care. She emphasized that rapid treatment is...
Novel Therapeutic and Trial Approaches for Lysosomal Storage Disorders with Polaryx’s Alex Yang — Episode 249
In episode 249 of the Xtalks Life Science Podcast, Alex Yang, JD, LLM, CEO of Polaryx, discusses the company’s mission to develop disease‑modifying small‑molecule therapies for rare pediatric lysosomal storage disorders. Yang leverages more than 25 years of experience across...
IBS Awareness Month 2026: The Hidden Realities of IBS and the IBS Treatment Market
April 2026 marks IBS Awareness Month, spotlighting a condition that affects roughly 10‑15% of the global population and often goes undiagnosed. The campaign emphasizes education, stigma reduction, and earlier detection to improve quality of life. Meanwhile, the global IBS treatment...
Loargys (Pegzilarginase) Wins FDA Nod for Ultrarare Metabolic Disorder After Earlier Setbacks
The U.S. FDA granted accelerated approval to Loargys (pegzilarginase‑nbln) for treating arginase‑1 deficiency (ARG1‑D), an ultrarare metabolic disorder affecting roughly 250 Americans. Loargys, a recombinant human arginase‑1 enzyme, is the first therapy shown to lower plasma arginine levels, achieving about...
Is AI Ready to Transform COA Development?
Artificial intelligence is reshaping clinical development by augmenting, not replacing, human expertise. AI already accelerates medical imaging, compound discovery and COVID‑19 vaccine modeling, compressing timelines from years to months. In clinical outcome assessment (COA) translation, AI can support draft translation...
MiniMed Unveils MiniMed Flex, Its Smallest Insulin Pump Yet
MiniMed secured FDA clearance for the MiniMed Flex, its smallest insulin pump yet, featuring a fully smartphone‑controlled, screenless design. The pocket‑sized device is roughly half the size of the 780G and holds a 300‑unit insulin reservoir while integrating continuous glucose...
Autoimmune Immunotherapy Is Shifting Upstream: AnaptysBio on Targeting Pathogenic Immune Cells
Autoimmune drug development is moving upstream, targeting pathogenic immune cells rather than single cytokines. AnaptysBio’s Chief Medical Officer, Paul Lizzul, highlighted the company’s cell‑selective immunomodulation strategy, including CD122 antagonism that modulates both CD4 helper and CD8 cytotoxic T cells. Early‑phase...
Psilocybin Treatments for Treatment-Resistant Depression with Compass Pathways’ Dr. Steve Levine — Episode 248
The Xtalks Life Science Podcast featured Dr. Steve Levine, Chief Patient Officer at Compass Pathways, discussing the company’s push to develop psilocybin‑based therapies for treatment‑resistant depression (TRD). Levine, a board‑certified psychiatrist and founder of Actify Neurotherapies, highlighted the clinical promise...
World Health Day 2026: Stand with Science and Global Health Equity
World Health Day 2026, observed on April 7, adopts the theme “Together for Health, Stand for Science,” urging global unity around science‑driven health solutions. The WHO highlights One Health—linking human, animal and environmental health—and convenes two flagship events: the One Health...
Syneos Health Expands China Operations with Bestudy CRO Acquisition
Syneos Health completed the acquisition of Shanghai‑based Bestudy Medical Technology on March 20, 2026, adding a fast‑growing Chinese CRO to its global network. Financial terms were not disclosed, and Bestudy will continue operating independently under its own brand. The deal...
New Zepbound Commercial “Watch This” Highlights Long-Term Impact
Eli Lilly launched a Super Bowl commercial for its tirzepatide‑based weight‑loss drug Zepbound, emphasizing real‑world confidence and long‑term health management. The ad cites clinical data showing an average 48‑lb (21%) weight loss and a head‑to‑head SURMOUNT‑5 trial where Zepbound achieved a...
BMS’ Sotyktu Receives FDA Expansion in Psoriatic Arthritis
Bristol Myers Squibb received FDA approval expanding Sotyktu (deucravacitinib) to treat adults with active psoriatic arthritis, making it the first oral selective TYK2 inhibitor for this indication. The label extension is backed by the POETYK PsA-1 and PsA-2 trials, where...
Top 5 Fastest Growing Pharma & Biotech Companies in Europe in 2026
A Financial Times analysis of Statista data identifies Europe’s five fastest‑growing pharma and biotech firms between 2021 and 2024. Italy’s Itaste Medical surged to €18.4 billion in sales, a 2,035% absolute growth, while the UK‑based Grow Group expanded cannabis‑based medicines to...
Top 3 Medtech Companies to Work for in Asia in 2026, Per Financial Times
Asia’s medtech sector is gaining momentum as Singapore became the first nation to achieve the WHO’s highest maturity level for medical‑device regulation, signaling stronger oversight across the product lifecycle. The Financial Times’ 2026 ranking spotlights three leading employers—Baxter International, Medtronic,...
First Surrogate Endpoint in Osteoporosis Clinical Trials with FNIH’s Dr. Tania Kamphaus — Episode 247
On December 2025 the FDA officially qualified dual‑energy X‑ray absorptiometry (DXA) bone density scans as the first surrogate endpoint for fracture outcomes in osteoporosis trials involving post‑menopausal women. The qualification, achieved through a request from the Foundation for the National...
Overcoming Drug Development Obstacles for Some of the Most Challenging Ischemic Conditions
DiaMedica Therapeutics is advancing a recombinant tissue kallikrein (KLK1) to treat ischemic stroke and preeclampsia, leveraging the kallikrein‑kinin pathway to restore microvascular flow. Early trials show maternal blood‑pressure reductions, improved uterine‑artery Doppler indices, and no detectable drug in fetal circulation,...
Top 30 Largest Publicly Traded Healthcare Companies in 2026 by Employee Number
The article ranks the 30 biggest publicly traded healthcare firms by employee headcount, highlighting UnitedHealth’s 400,000 staff and $447.6 billion revenue as the top entry. It notes a 56% jump in global healthcare deal volume to $403 billion in 2025, despite fewer...
Eikon Therapeutics IPO Brings in $381M for Oncology Pipeline
Eikon Therapeutics priced an upsized IPO of 21.2 million shares at $18, raising roughly $381 million and valuing the company at about $860 million. The California‑based biotech focuses on immune‑signaling, DNA‑repair and androgen‑receptor pathways, with its lead candidate EIK1001 – a TLR7/8 dual...
Designing Clinical Trials to Address Asthma and COPD Flare-Ups
Acute asthma and COPD exacerbations remain a costly, life‑threatening gap despite advances in chronic therapies. Connect Biopharma, led by Barry Quart, is the first biotech targeting these flare‑ups with a biologic that blocks IL‑4Rα, aiming to curb upstream inflammation. The...
What Determines Success in Complex MASH Clinical Research Today?
Recent FDA approvals of resmetirom and semaglutide have shifted MASH care from a treatment‑void to a therapeutic reality, prompting sponsors to redesign trial endpoints and enrollment strategies. Non‑invasive diagnostic tools are emerging as potential primary endpoints, reducing reliance on liver...
How Dompé Is Innovating in Neuro-Ophthalmology with the FDA’s CNPV Program
Dompe, a privately owned biopharma, is advancing an intranasal nerve growth factor (NGF) therapy to treat non‑arteritic anterior ischemic optic neuropathy (NAION), a leading cause of sudden vision loss affecting roughly 6,000 U.S. patients annually. The approach leverages NGF’s neuroprotective...
MedTech M&A in 2026: Tracking Deal Activity
Medtech M&A rebounded in 2025 and accelerated in 2026, with firms pursuing targeted acquisitions and divestitures across cardiovascular, diagnostics, and manufacturing. Notable deals include Boston Scientific’s $14.5 billion purchase of Penumbra, Danaher’s $9.9 billion acquisition of Masimo, and Blackstone/TPG’s $18.3 billion takeover of...
National Kidney Month 2026: Breakthrough Kidney Disease Therapies
National Kidney Month 2026 highlights a surge of disease‑modifying kidney therapies as chronic kidney disease affects roughly 35.5 million Americans and 10 % of the global population. Recent Phase III data cement SGLT2 inhibitors and Bayer’s finerenone as standards for slowing CKD progression...
Closing the 9-Year Gap: A New Biomarker Targets the Diagnostic Delay in Axial Spondyloarthritis
Axial spondyloarthritis affects about 1.4% of adults but patients wait an average of nine years for diagnosis in North America, far longer than rheumatoid arthritis. Augurex has introduced SPINEstat, an anti‑14‑3‑η multiplex blood test that can distinguish inflammatory back pain...
Rethinking Endocrine Therapy in ER-Positive Breast Cancer
Dr. Steven Quay, CEO of Atossa Therapeutics, highlighted a new focus on tolerability and prevention in estrogen‑receptor‑positive breast cancer, where five‑year survival now exceeds 90%. Atossa is developing a next‑generation SERM that aims to reduce side‑effects while maintaining efficacy and...
Veradermics $294.8M IPO to Fund Phase III Hair Loss Trials
Veradermics closed a $294.8 million IPO, pricing 17 dollars per share and debuting on the NYSE under the ticker MANE. The capital will fund its late‑stage clinical program for VDPHL01, an extended‑release oral minoxidil aimed at androgenetic alopecia. The company has completed...
From Insights to Impact: Rare Disease Therapies with UCB’s Dr. Kim Moran — Episode 246
UCB’s Senior Vice President Dr. Kim Moran discusses the company’s rare disease pipeline, including therapies for mitochondrial TK2 deficiency, on Xtalks Life Science Podcast episode 246. Moran, who pioneered UCB’s Insights‑to‑Impact function, explains how patient‑derived data informs strategy, digital transformation,...
What Matters More in DNA-Encoded Libraries: Size, Quality or Chemical Diversity?
DNA‑encoded libraries (DELs) enable billions of compounds to be screened, but X‑Chem argues that size alone does not predict success. By limiting synthesis to two‑three cycles, the company creates lead‑like molecules (350‑450 Da) with high three‑dimensional diversity, and its analysis of...
Agomab IPO Raises $200M to Fund Fibrosis Therapies
Agomab Therapeutics NV closed its Nasdaq IPO, raising roughly $200 million by selling 12.5 million American Depositary Shares at $16 each. The capital will fuel its fibrosis‑focused pipeline, beginning with ontunisertib, an oral TGFβ‑ALK5 inhibitor for fibrostenosing Crohn’s disease that achieved its...
Accrufer Becomes First FDA-Approved Prescription Iron Therapy for Children 10+
Shield Therapeutics announced that the FDA has approved Accrufer, its ferric maltol oral iron formulation, for children ages 10 and older, making it the first prescription oral iron therapy for this age group. The approval expands the drug’s label beyond...
Norgine Announces £23 Million Investment to Expand Medicines Manufacturing in Wales
Norgine announced a £23 million injection to expand its Hengoed, Wales, manufacturing site, taking total investment at the location to more than £50 million since 2022. The upgrade will add high‑speed, energy‑efficient production lines and increase warehousing capacity, allowing the company to...
SpyGlass Pharma IPO Raises $172.5M to Develop Implantable Eye Therapies
SpyGlass Pharma completed an IPO that raised $172.5 million, selling 10.78 million shares at $16 each and listing on Nasdaq under the ticker SGP. The company’s SpyGlass Platform uses small implants to deliver drugs inside the eye, with its lead BIM‑IOL system...
What Is Driving the Recent Wave of Layoffs in Biotech?
Biotech firms are cutting staff as venture‑capital inflows dry up, clinical‑trial setbacks mount, and operating costs climb. While breakthroughs in gene therapy, RNA therapeutics and precision medicine continue, companies are trimming non‑core programs to preserve cash. Strategic restructurings aim to...
Xtalks Featured Member: Giorgia Palano, Life Science Consultant, Knightec Group
Xtalks has spotlighted Giorgia Palano, PhD, a Life Science Consultant at Knightec Group, highlighting her expertise in validation strategies and regulatory compliance. Palano works with cross‑functional teams to ensure quality documentation and continuous improvement across complex life‑science operations. She emphasizes...
Oncolytic Virotherapies in Ovarian Cancer and NSCLC with Genelux CEO Thomas Zindrick — Episode 245
Genelux Corporation’s President and CEO Thomas Zindrick discussed the company’s oncolytic virotherapy programs targeting ovarian cancer and non‑small cell lung cancer on the Xtalks Life Science Podcast. The interview highlighted the therapeutic potential of engineered viruses to stimulate anti‑tumor immunity...
Bysanti FDA Approval for Bipolar I and Schizophrenia Marks Vanda’s Second Win in Two Months
Vanda Pharmaceuticals received FDA approval for Bysanti (milsaperidone) to treat acute manic or mixed episodes of bipolar I disorder and schizophrenia in adults. The approval introduces a new chemical entity in the atypical antipsychotic class that is bioequivalent to Vanda’s...
J&J Commits $1B to Next-Gen Cell Therapy Manufacturing in Pennsylvania
Johnson & Johnson announced a more than $1 billion investment to build a next‑generation cell and gene therapy manufacturing complex on a 154‑acre site in Montgomery County, Pennsylvania. Construction is slated to start in the second half of 2026, creating over...
Rethinking Idiopathic Pulmonary Fibrosis: Unmet Needs, Evolving Biology and the Future of Clinical Research
Idiopathic pulmonary fibrosis (IPF) continues to pose a severe, often late‑diagnosed respiratory challenge, with mortality exceeding many cancers. Boehringer Ingelheim’s Martin Beck highlighted the shift toward earlier detection using AI‑enhanced imaging and a broader view of IPF as a heterogeneous,...
How Takeda Is Harnessing RWE, Patient Insights and Human-Focused AI to Advance Global Access
Takeda is leveraging real‑world evidence (RWE) and human‑focused AI to reshape clinical trial design, patient access, and global market strategies. Chief Medical Officer Awny Farajallah highlights three pillars: robust evidence generation, capability building, and early patient access. RWE is used...
Leading Women CEOs Across Pharma and Biotech: A 2026 Snapshot
2026’s leading women CEOs in pharma and biotech are steering some of the industry’s biggest strategic moves, from multi‑billion‑dollar investments to landmark FDA approvals. The list includes Julie Kim’s upcoming Takeda leadership, Emma Walmsley’s transition at GSK, Reshma Kewalramani’s growth...
Rare Disease Day Insight: Epilepsy Care Gaps in Pregnancy with UCB’s Andrea Wilkinson — Episode 244
The Xtalks Life Science Podcast’s Episode 244 spotlights a persistent gap in epilepsy care for pregnant women, noting that fewer than 5% of clinical trials include this population. Andrea Wilkinson, UCB’s Global Head of Patient Engagement & Advocacy, discusses new...
Filkri Becomes Fifth FDA-Approved Neupogen Biosimilar
Accord BioPharma’s Filkri (filgrastim‑laha) received FDA approval as the fifth biosimilar to Amgen’s Neupogen. The indication set mirrors Neupogen’s, covering chemotherapy‑induced neutropenia, AML, bone‑marrow transplant, severe chronic neutropenia, and radiation‑induced syndrome. Approval was based on two randomized trials in healthy...
Denifanstat Posts Positive Phase III Results for Acne Treatment
Ascletis Pharma announced that its oral fatty‑acid‑synthase inhibitor denifanstat (ASC40) achieved positive Phase III results in moderate‑to‑severe acne vulgaris. In a 480‑patient double‑blind trial, 33% of participants reached clear or almost‑clear skin versus 15% on placebo, and an open‑label safety study...
Eli Lilly Invests $3.5B in Pennsylvania to Scale Next‑Gen Obesity Drug Manufacturing
Eli Lilly announced a $3.5 billion investment to build a new injectable‑medicine plant in Lehigh Valley, Pennsylvania. The facility, slated to break ground in 2026 and run by 2031, will focus on next‑generation obesity and metabolic drugs such as the triple‑agonist retatrutide....
Novartis Breaks Ground on $23B Biomedical Research Hub in San Diego
Novartis began construction of a new biomedical research hub in San Diego. The 466,000‑sq‑ft center, part of a $23 billion US R&D and manufacturing program, will house about 1,000 researchers and target neuroscience, oncology, global health, and age‑related diseases. Scheduled to...
Topical Adquey (Difamilast) Wins FDA Approval for Atopic Dermatitis
The U.S. Food and Drug Administration has granted approval to Adquey, a 1% difamilast topical ointment, for the treatment of mild-to-moderate atopic dermatitis in patients two years and older. Developed by Otsuka and licensed to Acrotech Biopharma, the product is...
